# SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

> **NCT07131319** · PHASE2,PHASE3 · RECRUITING · sponsor: **Second Affiliated Hospital of Nanchang University** · enrollment: 30 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **OTHER:** Spatially Fractionated Radiotherapy (SFRT)
- **DRUG:** Tislelizumab, Carboplatin, Pemetrexed
- **DRUG:** Tislelizumab, paclitaxel, Carboplatin

## Key facts

- **NCT ID:** NCT07131319
- **Lead sponsor:** Second Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-21
- **Primary completion:** 2026-04-15
- **Final completion:** 2026-04-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07131319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07131319, "SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07131319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*